相似文献
1
HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo.男男性行为人群中的 HIV 预防：替诺福韦艾拉酚胺复方制剂与安慰剂的比较。
J Infect Dis. 2024 Apr 12;229(4):1123-1130. doi: 10.1093/infdis/jiad507.
2
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和富马酸替诺福韦二吡呋酯用于 HIV 暴露前预防（DISCOVER）：一项随机、双盲、多中心、阳性对照、3 期、非劣效性临床试验的主要结果。
Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5.
3
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.利用恩曲他滨和替诺福韦酯的依从-疗效关系来计算背景 HIV 发病率：一项随机对照试验的二次分析。
J Int AIDS Soc. 2021 May;24(5):e25744. doi: 10.1002/jia2.25744.
4
PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.在性少数群体男性伴侣样本中，与富马酸替诺福韦二吡呋酯/恩曲他滨相比，替诺福韦艾拉酚胺/恩曲他滨显示出更高的依从性。
AIDS Behav. 2021 Apr;25(4):1299-1305. doi: 10.1007/s10461-020-03095-7. Epub 2020 Nov 18.
5
Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.HIV 暴露前预防用于 HIV 预防：美国预防服务工作组的更新证据报告和系统评价。
JAMA. 2023 Aug 22;330(8):746-763. doi: 10.1001/jama.2023.9865.
6
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.品牌替诺福韦艾拉酚胺/恩曲他滨与替诺福韦二吡呋酯/恩曲他滨仿制药用于 HIV 暴露前预防的比较定价：成本效果分析。
Ann Intern Med. 2020 May 5;172(9):583-590. doi: 10.7326/M19-3478. Epub 2020 Mar 10.
7
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和替诺福韦二吡呋酯用于 HIV-1 暴露前预防的长期安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的第 96 周结果。
Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0.
8
Pre-Exposure Prophylaxis for the Prevention of HIV-1: An Assessment of Oral Pre-Exposure Prophylaxis Usage Patterns, First Evidence of HIV-1, and HIV-1 Risk Factors in the United States.HIV-1 前暴露预防：美国口服前暴露预防使用模式、首例 HIV-1 及 HIV-1 风险因素评估。
AIDS Patient Care STDS. 2024 Nov;38(11):495-506. doi: 10.1089/apc.2024.0158. Epub 2024 Nov 7.
9
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand.探索变性男性中雄激素化激素疗法与口服暴露前预防药物（恩曲他滨/替诺福韦和恩曲他滨/丙酚替诺福韦）之间潜在的药物相互作用（iMACT研究）：泰国一项随机、开放标签的药代动力学研究。
J Int AIDS Soc. 2025 Apr;28(4):e26445. doi: 10.1002/jia2.26445.
10
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.简报：尿中恩曲他滨和替诺福韦浓度可作为 HIV 阴性男男性行为者近期抗逆转录病毒药物暴露的标志物。
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):252-256. doi: 10.1097/QAI.0000000000002133.
引用本文的文献
1
Keep asking: What do I want? What do I have? What do I do? : An approach for combining information to learn about a target population.不断追问：我想要什么？我拥有什么？我做了什么？：一种整合信息以了解目标人群的方法。
Eur J Epidemiol. 2025 May 28. doi: 10.1007/s10654-025-01222-z.
本文引用的文献
1
Bridged treatment comparisons: an illustrative application in HIV treatment.桥接治疗比较：在HIV治疗中的一个示例应用
Am J Epidemiol. 2025 Jun 3;194(6):1687-1694. doi: 10.1093/aje/kwae340.
2
Fusing trial data for treatment comparisons: Single vs multi-span bridging.融合临床试验数据进行治疗比较：单段与多段桥接。
Stat Med. 2024 Feb 20;43(4):793-815. doi: 10.1002/sim.9989. Epub 2023 Dec 18.
3
Factors associated with PrEP adherence among MSM living in Jackson, Mississippi.居住在密西西比州杰克逊市的男男性行为者中与暴露前预防依从性相关的因素。
J HIV AIDS Soc Serv. 2021;20(3):246-261. doi: 10.1080/15381501.2021.1956666. Epub 2021 Aug 6.
4
Statistical considerations for cross-sectional HIV incidence estimation based on recency test.基于近期检测的横断面 HIV 发病率估计的统计考虑因素。
Stat Med. 2022 Apr 15;41(8):1446-1461. doi: 10.1002/sim.9296. Epub 2022 Jan 4.
5
TWISTER PLOTS FOR TIME-TO-EVENT STUDIES.用于事件发生时间研究的扭曲图。
Am J Epidemiol. 2021 Dec 1;190(12):2730-2731. doi: 10.1093/aje/kwab231.
6
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.替诺福韦二吡呋酯在低、中、高依从性服用恩曲他滨/替诺福韦艾拉酚胺与恩曲他滨/替诺福韦富马酸酯时外周血单个核细胞中的浓度。
AIDS. 2021 Dec 1;35(15):2481-2487. doi: 10.1097/QAD.0000000000003062.
7
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.卡博特韦用于预防顺性别男性和跨性别女性中的 HIV。
N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016.
8
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和替诺福韦二吡呋酯用于 HIV-1 暴露前预防的长期安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的第 96 周结果。
Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0.
9
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.利用恩曲他滨和替诺福韦酯的依从-疗效关系来计算背景 HIV 发病率：一项随机对照试验的二次分析。
J Int AIDS Soc. 2021 May;24(5):e25744. doi: 10.1002/jia2.25744.
10
Fusion designs and estimators for treatment effects.融合设计和治疗效果的估计量。
Stat Med. 2021 Jun 15;40(13):3124-3137. doi: 10.1002/sim.8963. Epub 2021 Mar 29.
Zotero 插件